US5258453A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
Assignee: University of Utah
•
Filing: 1992-01-21
•
Granted: 1993-11-02
•
Expires: 2012-01-21
Abstract
Abstract Compositions for the treatment of cancerous tissues in warm-blooded animals containing both an anticancer drug and a photoactivatable drug attached to copolymeric carriers are made up of a member selected from the group consisting of (a) a copolymeric carrier having attached thereto both an anticancer drug and a photoactivatable drug, (b) a mixture of copolymeric carriers wherein one copolymeric carrier has attached an anticancer drug and the other copolymeric carrier has attached a photoactivatable drug and (c) a combination of (a) and (b). The anticancer drug is attached to the polymeric carrier by side-chains which are stable in the blood stream of the warm-blooded animal but susceptible to hydrolysis by lysosomal enzymes intracellularly. The photoactivatable drug is attached by either the same degradable side-chain or by a non-degradable attachment. The polymer carrier may optionally contain a targeting moiety. Upon administration polymeric macromolecules enter targeted cancer cells by pinocytosis which reduces the side effects normally elicited by the free drugs. A time lag is allowed following administration for optimal uptake of the copolymers in the cancerous tissue for the anticancer agent to begin to take effect. Then a light sources of the appropriate wavelength and energy is to activate the photoactivatable drug. The combined effect of the anticancer agent and photoactivatable drug provides greater cell destruction at reduced dosages and side effects.
Inventors
- 👤 Jindrich Kopecek
- 👤 Nancy L. Krinick
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-06 08:39
CPC Classifications
A; A61; A61K; A61K41/00; A61K41/0057; A61K41/0071; A61K47/00; A61K47/50; A61K47/51; A61K47/56; A61K47/58; Y; Y10; Y10S; Y10S530/00; Y10S530/81; Y10S530/811; Y10S530/812; Y10S530/815; Y10S530/816
Claims Analysis
Total Claims: 32
Claim 1
Independent Claim
164 words
A composition for the treatment of cancerous tissues in warm-blooded animals containing both an anticancer drug and a photoactivatable drug attached to copolymeric carriers comprising a member selected from the group consisting of (a) a copolymeric carrier having attached thereto both an anticancer drug and a photoactivatable drug, (b) a mixture of copolymeric carriers wherein one copolymeric carrier has attached thereto an anticancer drug and the other copolymeric carrier has attached thereto a photoactivatable drug and (c) a mixture of polymeric carriers wherein one copolymeric carrier has attached thereto both an anticancer drug and a photoactivatable drug and the other copolymeric carrier has attached thereto a member selected from the group consisting of an anticancer drug and a photoactivatable drug, with the proviso that said anticancer drug is attached to said polymeric carrier by side-chains which are stable in the blood stream of said warm-blooded animal but susceptible to hydrolysis by lysosomal enzymes intracellularly and wherein said polymeric carriers optionally contain a targeting moiety.
Claim 2
Dependent Claim
164 words
A composition for the treatment of cancerous tissues in warm-blooded animals containing both an anticancer drug and a photoactivatable drug attached to copolymeric carriers comprising a member selected from the group consisting of (a) a copolymeric carrier having attached thereto both an anticancer drug and a photoactivatable drug, (b) a mixture of copolymeric carriers wherein one copolymeric carrier has attached thereto an anticancer drug and the other copolymeric carrier has attached thereto a photoactivatable drug and (c) a mixture of polymeric carriers wherein one copolymeric carrier has attached thereto both an anticancer drug and a photoactivatable drug and the other copolymeric carrier has attached thereto a member selected from the group consisting of an anticancer drug and a photoactivatable drug, with the proviso that said anticancer drug is attached to said polymeric carrier by side-chains which are stable in the blood stream of said warm-blooded animal but susceptible to hydrolysis by lysosomal enzymes intracellularly and wherein said polymeric carriers optionally contain a targeting moiety.
Claim 3
Dependent Claim
77 words
A composition according to claim 1 wherein said polymeric carrier is made up of copolymerized comonomer units comprising (a) between about 5.0 to 99.7 mol % of underivatized comonomer units, (b) between about 0.2 to 20.0 mol % of derivatized comonomer units having attached thereto a member selected from the group consisting of said anticancer agent and said photoactivatable agent; and (c) between about 0 to 94.8 mol % of derivatized comonomer units containing said targeting moiety.
Claim 4
Dependent Claim
26 words
A composition according to claim 2 wherein said polymeric carrier contains between about 0.1 to 94.8 mol % of derivatized comonomer units containing said targeting moiety.
Claim 5
Dependent Claim
45 words
A composition according to claim 2 wherein said polymeric carrier is a copolymer containing underivatized and derivatized comonomer units selected from the group consisting of N-(2-hydroxypropyl)methacrylamide (HPMA), N-methylacrylamide, N,N-dialkylacrylamides, acrylic acid, methacrylic acid, polyamino acids, polysaccharides, copolymers containing polyethyleneoxide sequences and polyvinyl pyrrolidone-maleic anhydride copolymers.
Claim 6
Dependent Claim
38 words
A composition according to claim 4 wherein said anticancer drug is attached to said polymeric carrier by enzyme degradable side-chains selected from the group consisting of oligopeptide sequences, oligosaccharide sequences and structures similar to those in nucleic acids.
Claim 7
Dependent Claim
12 words
A composition according to claim 5 wherein said side-chain is an oligopeptide.
Claim 8
Dependent Claim
26 words
A composition according to claim 6 wherein said polymeric carrier is a copolymer prepared from the copolymerization of underivatized and derivatized comonomer units of N-(2-hydroxypropyl)methacrylamide (HPMA).
Claim 9
Dependent Claim
13 words
A composition according to claim 4 wherein said polymeric carrier is a polysaccharide.
Claim 10
Dependent Claim
11 words
A composition according to claim 8 wherein the polysaccharide is dextran.
Claim 11
Dependent Claim
23 words
A composition according to claim 4 wherein said polymeric carrier is a copolymer containing underivatized and derivatized units of polyvinyl pyrrolidone-maleic anhydride copolymers.
Claim 12
Dependent Claim
65 words
A composition according to claim 7 wherein the oligopeptide side-chain is a peptide selected from the group consisting of Gly-Gly, Gly-Phe-Gly, Gly-Phe-Phe, Gly-Leu-Gly, Gly-Val-Ala, Gly-Phe-Ala, Gly-Leu-Phe, Gly-Leu-Ala, Ala-Val-Ala, Gly-Phe-Leu-Gly (SEQ ID NO:1), Gly-Phe-Phe-Leu (SEQ ID NO:2), Gly-Leu-Leu-Gly (SEQ ID NO:3), Gly-Phe-Tyr-Ala (SEQ ID NO:4), Gly-Phe-Gly-Phe (SEQ ID NO:5), Ala-Gly-Val-Phe (SEQ ID NO:6), Gly-Phe-Phe-Gly (SEQ ID NO:7), Gly-Phe-Leu-Gly-Phe (SEQ ID NO:8), or Gly-Gly-Phe-Leu-Gly-Phe (SEQ ID NO:9).
Claim 13
Dependent Claim
16 words
A composition according to claim 11 wherein the side chain peptide is Gly-Phe-Leu-Gly (SEQ ID NO:1).
Claim 14
Dependent Claim
32 words
A composition according to claim 12 wherein said anticancer drug attached to said side-chain peptide is a member selected from the group consisting of adriamycin, daunomycin, melphalan and bleomycin and derivatives thereof.
Claim 15
Dependent Claim
12 words
A composition according to claim 13 wherein said anticancer drug is adriamycin.
Claim 16
Dependent Claim
20 words
A composition according to claim 7 wherein said photoactivatable drug is attached to said polymeric chain by a nondegradable spacer.
Claim 17
Dependent Claim
23 words
A composition according to claim 15 wherein said nondegradable spacer is a member selected from the group consisting of glycine, or ε-aminocaproic acid.
Claim 18
Dependent Claim
38 words
A composition according to claim 7 wherein said photoactivatable drug is attached to said polymeric carrier by enzyme degradable side-chains selected from the group consisting of oligopeptide sequences, oligosaccharide sequences and structures similar to those in nucleic acids.
Claim 19
Dependent Claim
12 words
A composition according to claim 17 wherein said side-chain is an oligopeptide.
Claim 20
Dependent Claim
65 words
A composition according to claim 18 wherein the oligopeptide side-chain is a peptide selected from the group consisting of Gly-Gly, Gly-Phe-Gly, Gly-Phe-Phe, Gly-Leu-Gly, Gly-Val-Ala, Gly-Phe-Ala, Gly-Leu-Phe, Gly-Leu-Ala, Ala-Val-Ala, Gly-Phe-Leu-Gly (SEQ ID NO:1), Gly-Phe-Phe-Leu (SEQ ID NO:2), Gly-Leu-Leu-Gly (SEQ ID NO:3), Gly-Phe-Tyr-Ala (SEQ ID NO:4), Gly-Phe-Gly-Phe (SEQ ID NO:5), Ala-Gly-Val-Phe (SEQ ID NO:6), Gly-Phe-Phe-Gly (SEQ ID NO:7), Gly-Phe-Leu-Gly-Phe (SEQ ID NO:8), or Gly-Gly-Phe-Leu-Gly-Phe (SEQ ID NO:9).
Claim 21
Dependent Claim
16 words
A composition according to claim 19 wherein the side chain peptide is Gly-Phe-Leu-Gly (SEQ ID NO:1).
Claim 22
Dependent Claim
31 words
A composition according to claim 19 wherein said photoactivatable drug is a member selected from the group consisting of porphyrins, phthalocyanines, purpurins, chlorins, naphthalocyanines, cationic dyes, and tetracyclines and derivatives thereof.
Claim 23
Dependent Claim
14 words
A composition according to claim 21 wherein said photoactivatable drug is a chlorin derivative.
Claim 24
Dependent Claim
15 words
A composition according to claim 22 wherein said chlorin derivative is meso-chlorin e 6 .
Claim 25
Dependent Claim
81 words
A composition according to claim 18 wherein both said anticancer agent and said photoactivatable drug are attached to said polymer chain by an oligopeptide side-chain which is a peptide selected from the group consisting of Gly-Gly, Gly-Phe-Gly, Gly-Phe-Phe, Gly-Leu-Gly, Gly-Val-Ala, Gly-Phe-Ala, Gly-Leu-Phe, Gly-Leu-Ala, Ala-Val-Ala, Gly-Phe-Leu-Gly (SEQ ID NO:1), Gly-Phe-Phe-Leu (SEQ ID NO:2), Gly-Leu-Leu-Gly (SEQ ID NO:3), Gly-Phe-Tyr-Ala (SEQ ID NO:4), Gly-Phe-Gly-Phe (SEQ ID NO:5), Ala-Gly-Val-Phe (SEQ ID NO:6), Gly-Phe-Phe-Gly (SEQ ID NO:7), Gly-Phe-Leu-Gly-Phe (SEQ ID NO:8), or Gly-Gly-Phe-Leu-Gly-Phe (SEQ ID NO:9).
Claim 26
Dependent Claim
52 words
A composition according to claim 24 wherein said photoactivatable drug is a member selected from the group consisting of adriamycin, daunomycin, melphalan and bleomycin and derivatives thereof and said photoactivatable drug is a member selected from the group consisting of porphyrins, phthalocyanines, purpurins, chlorins, naphthalocyanines, cationic dyes, and tetracyclines and derivatives thereof.
Claim 27
Dependent Claim
11 words
A composition according to claim 25 wherein said peptide is Gly-Phe-Leu-Gly.
Claim 28
Dependent Claim
20 words
A composition according to claim 26 wherein said anticancer drug is adriamycin and said photoactivatable drug is a chlorin derivative.
Claim 29
Dependent Claim
15 words
A composition according to claim 27 wherein said chlorin derivative is meso-chlorin e 6 .
Claim 30
Dependent Claim
29 words
A composition according to claim 4 wherein said copolymeric carrier is a polymeric carrier having both an anticancer drug and a photoactivatable drug attached to the same polymeric molecule.
Claim 31
Dependent Claim
37 words
A composition according to claim 4 wherein said polymeric carrier is a mixture of copolymeric carriers wherein one copolymeric carrier has attached thereto an anticancer drug and the other copolymeric carrier has attached thereto a photoactivatable drug.
Claim 32
Dependent Claim
54 words
A composition according to claim 4 wherein said polymeric carrier is a mixture of polymeric carriers wherein one copolymeric carrier has attached thereto both an anticancer drug and a photoactivatable drug and the other copolymeric carrier has attached thereto a member selected from the group consisting of an anticancer drug and a photoactivatable drug.
References Cited (Backward Citations)
US5037883A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-11-01 | 1997-05-03 | 1997-11-02 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-11-01 | 2001-05-03 | 2001-11-02 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-11-01 | 2005-05-03 | 2005-11-02 | $7700.00 | Window Closed / Lapsed |